The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.La présente invention concerne des stimulateurs ou des activateurs de guanylate cyclase soluble (sGC) avec des inhibiteurs de phosphodiestérase-5 (PDE5) et au moins un autre composé pharmacologique pour la préparation de médicaments pour le traitement de la fibrose kystique (FK).
